Our study’s findings, which emphasize the differential expression of SUCLG2 across these cellular subsets, offer novel insights into the metabolic reprogramming in PCa and its potential exploitation for therapeutic advances. The gene discussed is SUCLG2; the disease is posterior cortical atrophy.